Previous close | 7.36 |
Open | 7.41 |
Bid | 7.05 x 300 |
Ask | 8.20 x 100 |
Day's range | 6.94 - 7.91 |
52-week range | 2.84 - 11.50 |
Volume | |
Avg. volume | 7,252,498 |
Market cap | 389.252M |
Beta (5Y monthly) | 2.93 |
PE ratio (TTM) | N/A |
EPS (TTM) | -57.95 |
Earnings date | 12 Jun 2024 - 17 Jun 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 31.82 |
Aurora Cannabis (ACB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) – the Canadian based leading global medical cannabis company, in conjunction with MedReleaf Australia, is pleased to announce the expansion of its portfolio with the introduction of a new range of premium dried cannabis flower products. Now available for doctors to prescribe to patients in Australia, the new products developed by Aurora and manufactured at its EU-GMP and TGA-GMP certified facility, will be distributed by MedReleaf Australia, a premie
Here is how Adverum Biotechnologies (ADVM) and Aurora Cannabis Inc. (ACB) have performed compared to their sector so far this year.